依折麦布联合阿托伐他汀对缺血性脑卒中患者低密度脂蛋白胆固醇达标率、疗效及安全性的影响OA
Effects of Ezetimibe Combined with Atorvastatin on Low-Density Lipoprotein Cholesterol Target Achievement Rate,Efficacy,and Safety in Patients with Ischemic Stroke
目的:分析依折麦布联合阿托伐他汀对缺血性脑卒中(IS)患者低密度脂蛋白胆固醇(LDL-C)达标率、疗效及安全性的影响.方法:回顾性选取2021年1月～2023 年 8 月郑州大学附属郑州中心医院收治的111例 IS 患者作为研究对象.按照治疗方式的不同分为对照组(阿托伐他汀钙片20 mg/d 治疗,n=54)和观察组(依折麦布片10 mg/d联合阿托伐他汀钙片20 mg/d治疗,n=57).比较治疗前后两组患者高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)、甘油三酯(TG)、LDL-C 水平,LDL-C 达标率、再次住院治疗发生率、临床疗效及不良反应.结果:治疗 6 个月和治疗12 个月后,两组患者 HDL-C 水平均升高,且观察组高于对照组(P＜0.05);TC、TG、LDL-C 水平均降低,且观察组低于对照组(P＜0.05);LDL-C达标率均增加,且观察组高于对照组(P＜0.05);观察组再次住院治疗的发生率(12.28%)低于对照组(27.78%,P＜0.05);临床治疗总有效率(87.72%)高于对照组(72.22%,P＜0.05).两组患者不良反应总发生率比较无统计学差异(P＞0.05).结论:与单用阿托伐他汀 20 mg/d相比,依折麦布10 mg/d 联合阿托伐他汀 20 mg/d 可改善 IS 患者血脂谱,提高 LDL-C达标率,降低再次住院风险,且未增加不良反应发生风险.
Objective:To analyze the effects of ezetimibe combined with atorvastatin on the low-density lipoprotein cholesterol(LDL-C)target achievement rate,Efficacy,and safety in patients with ischemic stroke(IS).Methods:A retrospective study was conducted on 111 patients with cerebrovascular disease admitted to Zhengzhou Central Hospital Affiliated to Zhengzhou University from January 2021 to August 2023.According to different treatment regimens,patients were divided into a control group(atorvastatin calcium tablets 20 mg/d,n=54)and an observation group(ezetimibe 10 mg/d combined with atorvastatin calcium tablets 20 mg/d,n=57).Compare the levels of high-density lipoprotein cholesterol(HDL-C),total cholesterol(TC),triglycerides(TG),and LDL-C between the pre-and post-treatment groups,as well as the LDL-C achievement rate,rehospitalization rate,clinical efficacy,and adverse reactions.Results:After 6 and 12 months of treatment,HDL-C levels increased in both groups,and the observation group had higher levels than the control group(P<0.05).TC,TG,and LDL-C levels decreased in both groups,and the observation group had lower levels than the control group(P<0.05).The LDL-C target achievement rate increased in both groups,and the observation group had a higher rate than the control group(P<0.05).The incidence of hospital readmission in the observation group(12.28%)was lower than that in the control group(27.78%,P<0.05).The total clinical efficacy rate was higher in the observation group(87.72%)than in the control group(72.22%,P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Compared with atorvastatin 20 mg/d alone,ezetimibe 10 mg/d combined with atorvastatin 20 mg/d can improve the lipid profile,increase the LDL-C target achievement rate,reduce the risk of hospital readmission,and does not increase the risk of adverse reactions in patients with ischemic stroke.
赵鑫;孟琳;张珍珍;毛立武;刘俊中;李坤彬
郑州大学附属郑州中心医院,神经内科,郑州 450000郑州大学附属郑州中心医院,神经内科,郑州 450000郑州大学附属郑州中心医院,神经内科,郑州 450000郑州大学附属郑州中心医院,脑血管病介入科,郑州 450000郑州大学附属郑州中心医院,脑血管病介入科,郑州 450000郑州大学附属郑州中心医院,神经康复科,郑州 450000
医药卫生
缺血性脑卒中低密度脂蛋白依折麦布阿托伐他汀不良反应
ischemic strokelow-density lipoproteinezetimibeatorvastatinadverse reaction
《中国合理用药探索》 2026 (4)
60-66,7
河南省医学科技攻关计划联合共建项目(LHGJ20231012)
评论